These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27087201)

  • 1. Humira: the impending patent battles over adalimumab biosimilars.
    Norman P
    Pharm Pat Anal; 2016 May; 5(3):141-5. PubMed ID: 27087201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
    Storz U
    Hum Antibodies; 2017; 25(1-2):1-16. PubMed ID: 27792008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
    Coghlan J; He H; Schwendeman AS
    J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humira: the first $20 billion drug.
    Gibbons JB; Laber M; Bennett CL
    Am J Manag Care; 2023 Feb; 29(2):78-80. PubMed ID: 36811981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Biosimilars of Adalimumab.
    Kaushik VV
    J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humira
    Norman P
    Pharm Pat Anal; 2017 May; 6(3):89-90. PubMed ID: 28485681
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars: how similar?
    Strand V; Cronstein B
    Intern Med J; 2014 Mar; 44(3):218-23. PubMed ID: 24118772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
    Zhao S; Chadwick L; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in psoriasis: what can we expect?
    Radtke MA; Augustin M
    J Dtsch Dermatol Ges; 2014 Apr; 12(4):306-12. PubMed ID: 24698590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigating adalimumab biosimilars: an expert opinion.
    Abitbol V; Benkhalifa S; Habauzit C; Marotte H
    J Comp Eff Res; 2023 Nov; 12(11):e230117. PubMed ID: 37855223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enbrel and etanercept biosimilars: a tale of two patent systems.
    Norman P
    Pharm Pat Anal; 2017 Jan; 6(1):5-7. PubMed ID: 28201948
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
    Lu X; Hu R; Peng L; Liu M; Sun Z
    Front Immunol; 2021; 12():638444. PubMed ID: 33889152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17.
    Shin YK; Han WY; Kim SJ; Kim KW; Roh JW; Lee JB; Oh JS; Astier A
    Adv Ther; 2021 Nov; 38(11):5609-5622. PubMed ID: 34618346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological patent thickets and delayed access to biosimilars, an American problem.
    Goode R; Chao B
    J Law Biosci; 2022; 9(2):lsac022. PubMed ID: 36072417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
    Cisek S; Choi D; Stubbings J; Bhat S
    Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.